Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune‐Albright syndrome: an observational study

Denosumab (Dmab) treatment can benefit patients with fibrous dysplasia/McCune‐Albright syndrome (FD/MAS) by suppressing the receptor activator of nuclear factor κB ligand (RANKL)‐mediated increased bone resorption. However, limited data of two pediatric cases indicate that a rebound phenomenon may o...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Maartje E., Clerkx, Stance N., Winter, Elizabeth M., Pereira, Alberto M., van de Ven, Annenienke C., van de Sande, Michiel A.J., Appelman‐Dijkstra, Natasha M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518724/
https://www.ncbi.nlm.nih.gov/pubmed/34076303
http://dx.doi.org/10.1002/jbmr.4380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518724/
https://www.ncbi.nlm.nih.gov/pubmed/34076303
http://dx.doi.org/10.1002/jbmr.4380

Ejemplares similares